Author: Customer Service

31 January 2025 LEI: 2138003QW2ZAYZODBU23 WISDOMTREE MULTI ASSET ISSUER PUBLIC LIMITED COMPANY (THE “ISSUER”)(a public company incorporated with limited liability in Ireland) WISDOMTREE S&P 500 3X DAILY LEVERAGED (ISIN: IE00B7Y34M31)(THE “AFFECTED SECURITIES”) NOTIFICATION OF CHANGE IN THE DAILY SWAP FEE AND FUNDING SPREAD OF THE AFFECTED SECURITIES Terms not defined in this notice shall have the meaning ascribed to them in the Issuer’s Base Prospectus dated 5 September 2024. BNP Paribas acts as Swap Provider for the Affected Securities. The Issuer and the Swap Provider have agreed with the Issuer to reduce the Daily Swap Rate of the Affected Securities, as permitted pursuant to the terms of the Swap Provider Agreement and in accordance with paragraph 2.2(iii) of Annex A of the Conditions of the Affected Securities. The Issuer announces...

Transfer of the registered office Paris, France – (31 January 2025) — PROACTIS (ISIN code : FR0004052561) announces that its registered office has been transferred from 26-28, quai Gallieni – 92150 Suresnes to 54, rue de Londres – 75008 Paris. The company is now attached to the registry of the Tribunal des Affaires Economiques (formerly the Tribunal de Commerce) in Paris. PROACTIS’ Articles of Association have been amended accordingly. This transfer of the registered office is in line with the company’s policy of reducing its fixed costs. * * * * About Proactis SA (https://www.proactis.com/proactis-sa), a Proactis Company Proactis SA connects companies by providing business spend management and collaborative business process automation solutions for both goods and services, through The Business Network. Our solutions...

Dr. Sigurd Berven to Highlight NOCISCAN Capabilities, Combining MR Spectroscopy and Augmented Intelligence (AI)  NOCISCAN as New Gold Standard in Identifying a Source of Discogenic PainBROOMFIELD, Colo., Jan. 31, 2025 (GLOBE NEWSWIRE) — Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today its participation in the Selby Spine Conference. Renowned spine specialist, Dr. Sigurd Berven, will present Aclarion’s flagship platform, NOCISCAN, highlighting its innovative, evidence-supported capabilities. “Aclarion is pleased to have NOCISCAN featured at the Shelby Spine Conference,” said Ryan Bond, Chief Strategy Officer....

SANTIAGO, Chile, Jan. 31, 2025 (GLOBE NEWSWIRE) — Banco Santander Chile (NYSE: BSAC) announces that Mr. Andrés Trautmann Buc will take over as CEO and Country Head, replacing Mr. Román Blanco Reinosa. This change will occur on July 1, 2025 and, until then, Mr. Blanco will remain as the bank’s CEO, while Mr. Trautmann will continue to lead the Executive Vice President of Santander Corporate & Investment Banking (CIB). Mr. Trautmann, a commercial engineer from Universidad de Chile, has a distinguished career at Santander, since joining the Group in 2007. He began his career as Head of Institutional and Corporate Sales at Santander Chile. Between 2010 and 2012, he served as Head of Structured Products Sales in London for Santander UK. Between 2013 and 2018 he oversaw the Andean Zone sales for Goldman Sachs in New York....

As seen in the DESTINY-Breast06 trial, approximately 20-25 percent of hormone receptor (HR)-positive, HER2-negative breast cancer patients may be considered HER2-ultralow.1 These patients may now be eligible for a targeted treatment, which could significantly improve their outcomes. The PATHWAY HER2 (4B5) test, the first and only FDA approved companion diagnostic for assessing HER2-low status since 2022,  is now also approved to aid in the assessment of HER2-ultralow status for metastatic breast cancer patients. HER2 interpretation in breast cancer is evolving. With the introduction of HER2-low and now HER2-ultralow classifications, Roche continues to lead in HER2 diagnostics, helping to expand patient access to personalised treatment.Basel, 31 January 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food...

CORRECTION – Financial agenda for 2025 Villepinte, 13 janvier 2025: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, is announcing its financial agenda for 2025.Publications calendar2024 ANNUAL REVENUEFebruary 06, 2025, after trading2024 ANNUAL RESULTSMarch 26, 2025, after trading2025 1st QUARTER REVENUEApril 24, 2025, after tradingANNUAL SHAREHOLDERS’ MEETINGMay 23, 20252025 2nd QUARTER REVENUEJuly 24, 2025, after trading2025 FIRST HALF RESULTSSeptember 24, 2025, after trading2025 3rd QUARTER REVENUEOctober 23, 2025, after tradingAbout Guerbet At Guerbet, we build lasting relationships so that we enable people to live better. That is our purpose. We are a leader in medical imaging worldwide, offering a comprehensive...

The Ordinary General Meeting of Shareholders of 31 January 2025 approved all the proposed resolutions on the agenda, which mainly concerned the financial statements of Ascencio SA for the year ended at 30 September 2024. 1.893.843 shares of Ascencio SA were represented, or 29 % of the total number of shares in existence. Approval of the annual account s of Ascencio SA and appropriation of profitThe Meeting approved the distribution of a gross dividend of EUR 4.30 per share.The Meeting gave discharge, by separate vote, to the sole statutory director and the Statutory Auditor, SRL Deloitte, for the performance of their mandates.The Meeting approved, by separate vote, the compensation report and the provisions relating to the change of control.Lastly, the Meeting noted the resignation of Deloitte, having reached the maximum term of consecutive...

The Nomination Committee is a sub-committee of the Board of Directors which shall assist the Board with the process of Board succession planning, identification and nomination of Board candidates, alternate Board candidates as well as members of the Board‘s committees. Eimskip‘s Annual General Meeting will be held on 27 March 2025 and the Nomination Committee is now open for nominations. Declaration of candidacy shall be submitted to the committee on a special form that can be accessed at the Company‘s Investor website under AGM documents, and shall be returned to the email nominationcommittee@eimskip.com Deadline for declaring candidacy to the Nomination Committee passes at 12:00 (GMT) on Friday 14 February 2025. The committee reserves the right to discuss candidacies that are received later. All current members of the Board of Directors...